DUBLIN and SAN JOSE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) ...

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...

Medtronic (NYSE: MDT) today announced study results backing its adaptive DBS algorithm for personalized therapy in Parkinson's.

At Samsung Developer Conference 2019 today, Medtronic and Samsung showed off a Galaxy smartphone app, Patient Programmer, that allows patients to manage their own therapy for Parkinson’s disease.

Medtronic recently announced that the U.S. Food and Drug Administration (FDA) has approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. Medtronic’s DBS ...

Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This ...

Medtronic ($MDT) has earned a CE mark for its SureTune2 software. The tech offers physicians patient-specific visualizations which help them to “tune” a patient ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS programming ...

(BPT) – Parkinson’s Disease (PD) impacts up to one in 15 individuals in the United States. People with PD often experience symptoms that impact their movement, like tremors, shuffling feet while ...

Medtronic received a CE mark for a deep brain stimulation system that can not only deliver electrical therapy but also record the brain’s signals in order to adjust and personalize treatment. The ...